US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2024/25

EQL Pharma AB (publ) will publish its interim report for the second quarter, 2024/25, on Wednesday, November 6[th], before stock markets opening.At 10.00 (CET) 6[th] November, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/jszm8ecf Date and time November 6[th],

Bulletin from the annual general meeting in EQL Pharma AB on 19 August 2024

Today, on 19 August 2024, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.Resolution on adoption of accounts and allocation of the company’s result The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and the consolidated balance sheet. The annual general meeting also resolved to distribute the company’s result in accordance with the proposal from the board of directors in the annual report meaning that no dividends are paid for the financial year 2023/2024

Interim Report April - June 2024

Sales and operating profit growth, new products added to the pipelineApril - June · Consolidated sales during the first quarter, April to June amounted to SEK 82.8 (56.2) million, an increase of 47%. · Gross profit amounted to SEK 37.0 (26.2) million for the quarter, an increase of 41%. · EBIT amounted to SEK 15.2 (7.9) million, an increase of 92%. The operating margin was 18% (14%). · EBITDA margin was 19% (18%). · Costs related to preparations for uplisting to NASDAQ main list in the quarter of SEK 1.0 (0,2) million. Furthermore, extraordinary shipping costs linked to the

Notice of annual general meeting in EQL Pharma AB

The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Monday 19 August 2024 at 16.00 at the company’s premises at Stortorget 1 in Lund.Right to participate and notification Shareholders wishing to attend the annual general meeting must: · be registered in the company’s share register kept by Euroclear Sweden AB as of Friday 9 August 2024, and · notify the company of their intention to participate in the annual general meeting no later than Tuesday 13 August 2024 in writing by mail to EQL Pharma AB, Stortorget 1, SE-

Invitation to presentation in connection with EQL Pharma's interim report, first quarter, 2024/25

EQL Pharma AB (publ) will publish its interim report for the first quarter, 2024/25, on Thursday, August 8[th], before stock markets opening.At 10.00 (CET) 8[th] August, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/pftxx2ys Date and time August 8[th], 2024, at

Mellozzan[® ](melatonin) has gained marketing approval in Switzerland

EQL's key product Mellozzan[®] has now gained marketing approval by the Health Authorities in Switzerland, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH & Co. KG. Launch of Mellozzan in Switzerland is planned for the financial year 2024/25, subject to reimbursement approvals and manufacturing capabilities. In addition to Switzerland the licensee also has ongoing work for registrations and subsequent launches in Finland and the UK. In 2023, Medice launched Mellozzan[®] in Denmark and Norway and this year it was launched in Germany and Austria.

Trading in EQL Pharma’s shares on Nasdaq Stockholm commences today

EQL Pharma AB ("EQL Pharma" or the "Company") announced on 12 June 2024 that Nasdaq Stockholm’s listing committee has approved that the Company’s shares are admitted to trading on Nasdaq Stockholm Main Market and published a prospectus with regards to the list change on 28 June 2024. Today, on 4 July 2024, the trading in the Company’s share on Nasdaq Stockholm commences.CEO Axel Schörling comments: “The listing on Nasdaq Main Market gives us a quality stamp and is a natural step in EQL Pharma’s growth story. Our current annual revenue growth rate is around 40%, and we aim to continue to be

EQL Pharma AB publishes prospectus for list change to Nasdaq Stockholm

EQL Pharma AB ("EQL Pharma" or the "Company") announced on 12 June 2024 that Nasdaq Stockholm’s listing committee has approved that the Company’s shares are admitted to trading on Nasdaq Stockholm Main Market. The prospectus that has been prepared in connection with the list change has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is now available on EQL Pharma’s website, www.eqlpharma.com, and will be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.A listing of the Company’s shares on Nasdaq

EQL Pharma AB has been approved for listing on Nasdaq Stockholm

Nasdaq Stockholm’s listing committee has today announced that it considers that EQL Pharma AB ("EQL Pharma" or the "Company") meets the applicable listing requirements and that they will approve the application for admission to trading of the Company’s shares on Nasdaq Stockholm Main Market subject to customary conditions being met, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and the fulfilment of the distribution requirement for the Company’s shares. The first day of trading on Nasdaq Stockholm is expected to

EQL Pharma's CEO increases his holding in the company

EQL Pharma's CEO, Axel Schörling, has increased his stake in the company. During the period 22-24 May, Axel Schörling has bought 53,903 shares in the Company at a volume-weighted average price of SEK 47.05, a transaction totalling SEK 2,536,010. The trades were made on Spotlight Stock Market. After the purchases, Schörling owns a total of 311,016 shares, which corresponds to 1.1% of the shares in the Company. This makes him EQL's 3rd largest physical owner and the 9th largest, institutions included."It feels absolutely right for me to increase my ownership in EQL," says Axel Schörling. "

Year-end Report April 2023 – March 2024

Good growth and record amount of launches January - March 2024 · Consolidated sales during the fourth quarter, January to March amounted to SEK 78.1 (60.3) million, an increase of 30%. Adjusted for non-recurring sales in the comparative quarter Q4 2022/23, the revenue amounted to 78.1 (53.5) MSEK, an increase of 46%. · Gross profit amounted to SEK 31.5 (28.1) million for the quarter, an increase of 11%. · EBIT amounted to SEK 8.4 (6.1) million, an increase of 38%. The operating margin was 11% (10%). · EBITDA margin was 14%. · Costs related to preparations for uplisting to

Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2023/24

EQL Pharma AB (publ) will publish its year-end report for the fourth quarter, 2023/24, on Tuesday, May 14[th], after stock markets closing.At 10.00 (CET) 15[th] May, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the year-end report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/ysf2a9te Date and time May 15[th], 2024, at 10.

Mellozzan[® ](melatonin) launched in Germany and Austria

EQL's key product Mellozzan[®] has now been launched in Germany and Austria, where it is provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH & Co. KG. In addition to Germany and Austria, Medice also has ongoing work with registrations in Finland and Switzerland and launch in the UK. In 2023, Medice launched Mellozzan[®] in Denmark and Norway.In parallel with the launch, work is ongoing to get Mellozzan[®] reimbursed in Germany, Austria and the UK. Until that happens, patients will have to pay for the medicine out of pocket which will limit sales initially. This is

Mellozzan[® ](melatonin) have gained marketing approval in the UK

EQL's key product Mellozzan[®] has now gained marketing approval by the Health Authorities in the UK, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH & Co. KG. Launch of Mellozzan in the UK is planned for the financial year 2024/25, subject to reimbursement approvals and manufacturing capabilities. In addition to the UK the licensee also has ongoing work for registrations and subsequent launches in Finland and Switzerland. In 2023, Medice launched Mellozzan[®] in Denmark and Norway and launch preparations are nearing completion in Germany and

Nomination committee for the 2024 Annual General Meeting

According to the resolution of the 2023 Annual General Meeting, the Nomination Committee shall be convened by the Chairman of the Board and consist of a representative of each of the three largest shareholders in terms of the number of votes at the end of December 2023.At the end of December, the three largest shareholders were Cadila Pharmaceuticals Ltd. and Fårö Capital AB and SEB Fonder. All have agreed to participate in the nomination committee's work. Prior to the 2024 Annual General Meeting, the Nomination Committee consists of Christer Fåhraeus (appointed by Fårö Capital AB),

Interim Report April - December 2023

Growth and profitability despite large impact from the global antibiotics shortage and continued expansion of pipelineOctober - December 2023 · Consolidated sales during the third quarter, October to December amounted to SEK 70.2 (80.2) million. Adjusted for non-recurring sales in the comparative quarter Q3 2022/23, the revenue amounted to 70.2 (56.1) MSEK, an increase of 25%. · Gross profit amounted to SEK 33.5 (35.5) million for the quarter, but the gross margin increased from 44% to 48%. · EBIT amounted to SEK 9.8 (15.5) million, a decrease of 37%. The operating margin was 14%

Invitation to presentation in connection with EQL Pharma's quarterly report, third quarter, 2023/24

EQL Pharma AB (publ) will publish its quarterly report for the third quarter, 2023/24, on Tuesday, February 13[th], after stock markets closing. At 10.00 (CET) 14[th] February, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the quarterly report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: http://tinyurl.com/ny96c56nDate and time February 14[th],

EQL Pharma again appointed Gazelle company in Skåne by Dagens Industri and once again places itself in 6th place out of 98 Skåne Gazelles

Every year, Dagens Industri appoints Sweden's fastest growing company to the so-called Gazelle company. It is an award to support and encourage Swedish entrepreneurs to grow.The following criteria apply to receive the award: 1. A net turnover that exceeds SEK 10 million, according to the latest annual report. 2. At least ten employees, according to the latest annual report. 3. At least doubled its turnover, if you compare the first and last financial year in the four-year study period. 4. Increased its turnover every year for the last three years. 5. A positive overall operating

Interim Report April - September 2023

Growth despite large impact from the global antibiotics shortage, several important MA approvals and expansion of pipelineJuly - September 2023 · Consolidated sales during the second quarter, July to September amounted to SEK 59.6 (73.3) million. Adjusted for non-recurring sales the revenue amounted to 59.6 (51.2) MSEK, an increase of 16%. · Gross profit amounted to SEK 23.9 (28.6) million for the quarter, a decrease of 16%. · EBIT amounted to SEK 6.6 (11.9) million, a decrease of 45%. The operating margin was 11% (16%). · EBITDA margin was 14%. · Earnings per share before

Invitation to presentation in connection with EQL Pharma's quarterly report, second quarter, 2023/24

EQL Pharma AB (publ) will publish its quarterly report for the second quarter, 2023/24, on Friday, November 17[th], before stock markets opening.At 10.00 (CET) 17[th] November, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the quarterly report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/mpzed7uf  Date and time November 17[

Mellozzan[® ](melatonin) have gained marketing approval in Germany and Austria

As the first countries outside of Scandinavia, EQL's key product Mellozzan[®] has now gained marketing approval by the Health Authorities in Germany and Austria, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH & Co. KG. Launch of Mellozzan in Germany and Austria are planned for 2024, subject to reimbursement approvals and manufacturing capabilities. In addition to Germany and Austria the licensee also has ongoing work for registrations and subsequent launches in the UK, Finland and Switzerland. Earlier this year Medice launched Mellozzan in

Bulletin from the annual general meeting in EQL Pharma AB on 17 August 2023

Today, on 17 August 2023, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.Resolution on adoption of accounts and allocation of the company’s result The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and the consolidated balance sheet. The annual general meeting also resolved to distribute the company’s result in accordance with the proposal from the board of directors in the annual report meaning that no dividends are paid for the financial year 2022/2023

Interim Report April - June 2023

Solid operating profit without Covid-19 tests, a continued growing pipeline and a new strategic key productApril - June 2023 · Consolidated sales during the first quarter, April to June amounted to SEK 56.2 (46.1) million. Adjusted for non-recurring sales the revenue amounted to 56.2 (43.0) MSEK, a decrease of 31%. · Gross profit amounted to SEK 26.2 (23.7) million for the quarter, a decrease of 11%. · EBIT amounted to SEK 7.9 (7.9) million, a decrease of 0,1%. The operating margin was 14% (17%). · EBITDA margin was 18% - this margin is from now on reported separately as it is

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe